NASDAQ · Healthcare · Biotechnology
Telix Pharmaceuticals Limited
TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. CEO Christian Behrenbruch · Market cap $3.6B.
$10.52
+0.13 · +1.25%
52w hi $18.4952w lo $6.28
Off 52w high 39.9%
59
ROUTINE
Current InsiderScore
Corp · 90d
2
2 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
0
0 strong · 0 notable
Analyst consensus
Strong Buy
Avg PT $17.00
Section 01
Recent Form 4 filings
2 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Apr 29 | Christian Behrenbruch | MD & Group CEO | Buy | 33,435 | $14.87 | +$497K | 59 |
| Apr 28 | Christian Behrenbruch | MD & Group CEO | Buy | 34,500 | $14.48 | +$500K | 59 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
JunJulAugSepOctNovDecJanFebMarAprMay